Tarsus Pharmaceuticals completes acquisition of Alkeus, adding Stargardt Phase 3 drug
Tarsus Pharmaceuticals completed its acquisition of Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine targeting Stargardt’s disease biology. The deal strengthens its eye-care pipeline.
Story updates
12:39:04 PM UTC
SquawkNews
Tarsus Pharmaceuticals Completes Acquisition Of Alkeus Pharmaceuticals, Expanding Leadership In Eye Care >TARS
12:47:37 PM UTC
SquawkNews
Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapyStrengthens Tarsus’ differentiated pipeline and leadership in eye careIRVINE, Calif., Sep…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.